17th CLUB PHASE 1
ANNUAL MEETING
05 April 2018
Paris

Location
Maison de la Chimie
28, rue Saint Dominique
75007 PARIS
France
Phone: (+33)1 40 62 27 00

Access
RER: Line C, Invalides Station
Subway: Lines 8, 12 and 13, Assemblée Nationale, Solférino or Invalides Stations
Bus: Lines 63, 69, 83, 93 and 94

Registration
Required before 30 March 2018

Cost (without accommodation)
Club Phase I - 17th annual meeting only (05 April 2018):
Member (2018): 200 €
Non-Member: 300 €
Club Phase I - 17th annual meeting + PBPK symposium (04 and 05 April 2018):
Member (2018): 300 €
Non-Member: 400 €

Limited number of seats

Closest hotels
Saint-Dominique Hotel
62, rue Saint-Dominique

Best Western Tour Eiffel Invalides
35, boulevard de la Tour-Maubourg

Hôtel de Varenne
44, rue de Bourgogne

Booking directly with the Hotel.

Contact
leclubphase1@gmail.com

Registration form online on www.clubphase1.fr

Organisation Committee:
Club Phase 1 Board

Club Phase I (Association Loi 1901) a founding member of

Association des professionnels du développement précoce du médicament
Final Programme

08.30-09.00
Welcome coffee/tea

Morning Sessions

09.00-09.10
Welcome from the Club Phase 1 President

09.10-09.50
From biomarkers for patient selection to companion diagnostic in drug development
Gérard Sanderink, Sanofi, France

09.50-10.30
Advances in ECG safety: Phase 1 studies supporting TQT waivers
Pierre Maison-Blanche, Bichat University Hospital, APHP, France

10.30-11.00
Break

11.00-11.40
Metabolite profiling in early clinical drug development: Current status and future prospects
Mike Ufer, Idorsia Pharmaceuticals Ltd, Switzerland

11.40-12.30
PIPs’ experience after 10 years: Inclusion of the paediatric development early is necessary when requested by regulation
Sylvie Benchetrit, French referent to the EMA PDCO, France

12.30-14.00
Lunch

Afternoon Sessions

14.00-14.30
Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474
Pr. Mario Van Der Stelt, Leiden University, The Netherlands

14.30-15.00
In silico tools for early phase side effect profiling and off target prediction of potential drug candidates
Pr. Thierry Langer, Prestwick Chemical referent, Vienna University, Austria

15.00-15.20
Panel discussion with Pr. Van Der Stelt, Pr. Thierry Langer and the audience

15.20-15.50
Break

15.50-16.30
CAR T-cell: Engineering immune cells to treat cancer
Roman Galetto, Cellectis SA, France

16.30-17.10
Central Nervous System biomarkers with a special focus on electrophysiology
Alain Patat, Biotrial, France

17.10-17.30
Conclusions and presentation of the next events of the Club Phase 1

Club Phase I (Association Loi 1901) a founding member of